Canadian Medical Cannabis Industry partners with Leading Physician Consortium

Five-city cross-Canada program to provide cannabinoid education for health care professionals

OTTAWA – November 4, 2014The Board of Directors of the Canadian Medical Cannabis Industry Association (CMCIA) today announced a partnership with the Canadian Consortium for the Investigation of Cannabinoids (CCIC) to support, through an unrestricted grant, a 5-City Continuing Medical Education (CME) program to be held in February-March 2015.

This educational initiative aims to provide balanced and evidence based cannabinoid education to Canadian healthcare practitioners (physicians and nurse practitioners). The program builds on the portfolio of successful and respected educational sessions led by the CCIC since 2007. The program objectives and contents are developed by a national steering committee and are totally independent from funding sources.

Regulatory changes by Health Canada’s Marihuana for Medical Purposes Regulations (MMPR) that took effect last April made physicians directly responsible for deciding who should legally have access to marijuana for medical purposes.

“As physicians our number one priority is to help patients. It is imperative that physicians have sufficient knowledge about cannabis and cannabinoids in order to engage in informed discussions with patients about the therapeutic use of these drugs” said Dr. Mark Ware, Executive Director of the CCIC. “The CMCIA sponsored education program will build greater awareness of the risks and benefits of cannabinoids among Canadian physicians. We are encouraged to see the industry supporting this important work. We hope this is the beginning of an important partnership between physicians, researchers and the medical cannabis industry” Ware continued.

As the national association representing the majority of licensed producers regulated by Health Canada under the MMPR, the CMCIA is pleased to support unbiased independent research presented directly to physicians by physicians.

“A key area of focus for the CMCIA is to address the identified need for physician education on both the therapeutic risks and benefits of medical marijuana” said Marc Wayne, Chair of CMCIA.

“The time has come to address these gaps head on and work collectively to support members of the medical community so they can provide the best treatment for their patients. I am very pleased to see members of our industry leading this effort and working collaboratively to support these important initiatives. This program will help to reduce the stigma associated with the use of medical cannabis.”

The 5-city tour is expected to travel to Halifax, Montreal, Ottawa, Calgary and Vancouver.

The CMCIA would like to thank the following members who are supporting this important CME Education tour:

ABcannAgrimaBedrocan CanadaCannMedica PharmaMedCannAccessMedReleafMettrumOrganiGram, and Tweed.

About the CMCIA

The Canadian Medical Cannabis Industry Association (CMCIA) is Canada’s leading member-driven association for Licensed Producers (LPs) of medical cannabis. We represent the majority of producers currently licensed under the Health Canada’s Marijuana for Medical Purposes Regulations (MMPR), in force as of June 19, 2013.

The CMCIA’s mission is to promote national standards and best practices by supporting the development, growth and integrity of the medical cannabis industry. The association acts as a national voice for our members, and serves as a credible and trusted resource on issues related to medical cannabis industry.

The group shares a philosophy of patient-centered care and improved public health, and is committed to product safety and quality, secure and reliable access for qualified patients, and promotion of the safe and effective use of cannabis for medical purposes.

About the CCIC

The CCIC is a federally registered Canadian nonprofit organization of basic and clinical researchers and health care professionals established to promote evidence-based research and education concerning the endocannabinoid system and therapeutic applications of endocannabinoid and cannabinoid agents.

www.ccic.net

For more information or interviews, please contact:

Kristina Martin, Communications, CMCIA
T: 613-235-0221 ext. 226
E: comms@cmcia.ca

Marc Wayne
Chair of the Board of Directors, CMCIA
T: 416-943-5800 ext. 201
E: chair@cmcia.ca

Dr. Mark Ware
Executive Director, CCIC
E: mware@ccic.net
M: (514) 951-6330